New therapy to overcome treatment-resistant skin cancers
A study has revealed why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and identifies a new combination treatment.
Publishing in Nature Immunology, the international group of experts led by scientists at Newcastle University, UK has identified the biological mechanisms leading to a revolution in our understanding of ICB resistance.
They identify a new combination strategy for treating ICB resistant metastatic skin cancers and suggest that this can also be of benefit in the immunotherapy treatment of other solid cancers.
Dr Shoba Amarnath, Reader in Immune Regulation at Newcastle University led the research. ...